These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11378009)

  • 1. A cost-effectiveness analysis of bisoprolol for heart failure.
    Varney S
    Eur J Heart Fail; 2001 Jun; 3(3):365-71. PubMed ID: 11378009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Congestive heart failure in Spain: cost-effectiveness and cost-benefit analyses of treatment with beta-blockers].
    Díez Manglano J
    Rev Clin Esp; 2005 Apr; 205(4):149-56. PubMed ID: 15860185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
    Eur Heart J; 2001 Jun; 22(12):1021-31. PubMed ID: 11428837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Economic analysis of the treatment of heart failure with beta-blockers].
    Díez-Manglano J
    Med Clin (Barc); 2013 Sep; 141(6):265-70. PubMed ID: 23597957
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost effectiveness of carvedilol for heart failure.
    Delea TE; Vera-Llonch M; Richner RE; Fowler MB; Oster G
    Am J Cardiol; 1999 Mar; 83(6):890-6. PubMed ID: 10190405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In heart failure, all beta-blockers are not necessarily equal.
    Tang WH; Militello M; Francis GS
    Cleve Clin J Med; 2003 Dec; 70(12):1081-7. PubMed ID: 14686687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cost-effectiveness of bisoprolol in chronic heart failure].
    Ekman M; Zethraeus N; Dahlström U; Höglund C
    Lakartidningen; 2002 Feb; 99(7):646-50. PubMed ID: 11887711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of bisoprolol treatment for heart failure.
    Di Stasi F; Scalone L; De Portu S; Menditto E; Mantovani LG
    Ital Heart J; 2005 Dec; 6(12):950-5. PubMed ID: 16502708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].
    Schädlich PK; Paschen B; Brecht JG
    Med Klin (Munich); 1997 Aug; 92(8):499-504. PubMed ID: 9340476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness results from the US Carvedilol Heart Failure Trials Program.
    Vera-Llonch M; Menzin J; Richner RE; Oster G
    Ann Pharmacother; 2001; 35(7-8):846-51. PubMed ID: 11485131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bisprolol in heart failure: efficacy and costs in a French setting according to CIBIS II].
    Lévy P; Mérot JL; Lechat P; Lévy E; Bogillot O
    Therapie; 2001; 56(4):421-5. PubMed ID: 11677866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of beta blocker therapy for patients with chronic severe heart failure in Ireland.
    Barry M
    Ir Med J; 2002 Jun; 95(6):174, 176-7. PubMed ID: 12171265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study for the Federal Republic of Germany.
    Schädlich PK; Paschen B; Brecht JG
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):147-55. PubMed ID: 10176149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of beta blockade in heart failure.
    Gregory D; Udelson JE; Konstam MA
    Am J Med; 2001 May; 110 Suppl 7A():74S-80S. PubMed ID: 11334781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom.
    Stewart S; McMurray JJ; Hebborn A; Coats AJ; Packer M;
    Int J Cardiol; 2005 Apr; 100(1):143-9. PubMed ID: 15820297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada.
    Levy AR; Briggs AH; Demers C; O'Brien BJ
    Am Heart J; 2001 Sep; 142(3):537-43. PubMed ID: 11526370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study.
    Levy P; Lechat P; Leizorovicz A; Levy E
    Cardiovasc Drugs Ther; 1998 Jul; 12(3):301-5. PubMed ID: 9784910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Older adults with heart failure treated with carvedilol, bisoprolol, or metoprolol tartrate: risk of mortality.
    Perreault S; de Denus S; White M; White-Guay B; Bouvier M; Dorais M; Dubé MP; Rouleau JL; Tardif JC; Jenna S; Haibe-Kains B; Leduc R; Deblois D
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):81-90. PubMed ID: 27859924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Economic study of carvedilol in heart failure. A cost effectiveness study in France].
    Lévy P; Dubois-Randé JL; Cohen-Solal A; Lévy E
    Arch Mal Coeur Vaiss; 2001 Feb; 94(2):166-70. PubMed ID: 11265558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Benefits of Carvedilol, Bisoprolol, and Metoprolol Controlled Release/Extended Release in Hemodialysis Patients with Heart Failure: A 10-Year Cohort.
    Tang CH; Wang CC; Chen TH; Hong CY; Sue YM
    J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26738790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.